These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 24385930)

  • 1. Truncation of Ube3a-ATS unsilences paternal Ube3a and ameliorates behavioral defects in the Angelman syndrome mouse model.
    Meng L; Person RE; Huang W; Zhu PJ; Costa-Mattioli M; Beaudet AL
    PLoS Genet; 2013; 9(12):e1004039. PubMed ID: 24385930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A high-fidelity RNA-targeting Cas13 restores paternal Ube3a expression and improves motor functions in Angelman syndrome mice.
    Li J; Shen Z; Liu Y; Yan Z; Liu Y; Lin X; Tang J; Lv R; Geng G; Xiong ZQ; Zhou C; Yang H
    Mol Ther; 2023 Jul; 31(7):2286-2295. PubMed ID: 36805082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ube3a unsilencer for the potential treatment of Angelman syndrome.
    Vihma H; Li K; Welton-Arndt A; Smith AL; Bettadapur KR; Gilmore RB; Gao E; Cotney JL; Huang HC; Collins JL; Chamberlain SJ; Lee HM; Aubé J; Philpot BD
    Nat Commun; 2024 Jul; 15(1):5558. PubMed ID: 38977672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cas9 gene therapy for Angelman syndrome traps Ube3a-ATS long non-coding RNA.
    Wolter JM; Mao H; Fragola G; Simon JM; Krantz JL; Bazick HO; Oztemiz B; Stein JL; Zylka MJ
    Nature; 2020 Nov; 587(7833):281-284. PubMed ID: 33087932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent neuronal Ube3a expression in the suprachiasmatic nucleus of Angelman syndrome model mice.
    Jones KA; Han JE; DeBruyne JP; Philpot BD
    Sci Rep; 2016 Jun; 6():28238. PubMed ID: 27306933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome.
    Lee D; Chen W; Kaku HN; Zhuo X; Chao ES; Soriano A; Kuncheria A; Flores S; Kim JH; Rivera A; Rigo F; Jafar-Nejad P; Beaudet AL; Caudill MS; Xue M
    Elife; 2023 Jan; 12():. PubMed ID: 36594817
    [No Abstract]   [Full Text] [Related]  

  • 7. Ube3a imprinting impairs circadian robustness in Angelman syndrome models.
    Shi SQ; Bichell TJ; Ihrie RA; Johnson CH
    Curr Biol; 2015 Mar; 25(5):537-45. PubMed ID: 25660546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional reprogramming restores UBE3A brain-wide and rescues behavioral phenotypes in an Angelman syndrome mouse model.
    O'Geen H; Beitnere U; Garcia MS; Adhikari A; Cameron DL; Fenton TA; Copping NA; Deng P; Lock S; Halmai JANM; Villegas IJ; Liu J; Wang D; Fink KD; Silverman JL; Segal DJ
    Mol Ther; 2023 Apr; 31(4):1088-1105. PubMed ID: 36641623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular epigenetics of Angelman syndrome.
    Lalande M; Calciano MA
    Cell Mol Life Sci; 2007 Apr; 64(7-8):947-60. PubMed ID: 17347796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic imprinting does not reduce the dosage of UBE3A in neurons.
    Hillman PR; Christian SGB; Doan R; Cohen ND; Konganti K; Douglas K; Wang X; Samollow PB; Dindot SV
    Epigenetics Chromatin; 2017; 10():27. PubMed ID: 28515788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel intragenic deletions within the UBE3A gene in two unrelated patients with Angelman syndrome: case report and review of the literature.
    Aguilera C; Viñas-Jornet M; Baena N; Gabau E; Fernández C; Capdevila N; Cirkovic S; Sarajlija A; Miskovic M; Radivojevic D; Ruiz A; Guitart M
    BMC Med Genet; 2017 Nov; 18(1):137. PubMed ID: 29162042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein Delivery of an Artificial Transcription Factor Restores Widespread Ube3a Expression in an Angelman Syndrome Mouse Brain.
    Bailus BJ; Pyles B; McAlister MM; O'Geen H; Lockwood SH; Adams AN; Nguyen JT; Yu A; Berman RF; Segal DJ
    Mol Ther; 2016 Mar; 24(3):548-55. PubMed ID: 26727042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UBE3A reinstatement as a disease-modifying therapy for Angelman syndrome.
    Elgersma Y; Sonzogni M
    Dev Med Child Neurol; 2021 Jul; 63(7):802-807. PubMed ID: 33543479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prenatal delivery of a therapeutic antisense oligonucleotide achieves broad biodistribution in the brain and ameliorates Angelman syndrome phenotype in mice.
    Clarke MT; Remesal L; Lentz L; Tan DJ; Young D; Thapa S; Namuduri SR; Borges B; Kirn G; Valencia J; Lopez ME; Lui JH; Shiow LR; Dindot S; Villeda S; Sanders SJ; MacKenzie TC
    Mol Ther; 2024 Apr; 32(4):935-951. PubMed ID: 38327047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuronal overexpression of Ube3a isoform 2 causes behavioral impairments and neuroanatomical pathology relevant to 15q11.2-q13.3 duplication syndrome.
    Copping NA; Christian SGB; Ritter DJ; Islam MS; Buscher N; Zolkowska D; Pride MC; Berg EL; LaSalle JM; Ellegood J; Lerch JP; Reiter LT; Silverman JL; Dindot SV
    Hum Mol Genet; 2017 Oct; 26(20):3995-4010. PubMed ID: 29016856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adult
    Rotaru DC; van Woerden GM; Wallaard I; Elgersma Y
    J Neurosci; 2018 Sep; 38(37):8011-8030. PubMed ID: 30082419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translational outcomes in a full gene deletion of ubiquitin protein ligase E3A rat model of Angelman syndrome.
    Berg EL; Pride MC; Petkova SP; Lee RD; Copping NA; Shen Y; Adhikari A; Fenton TA; Pedersen LR; Noakes LS; Nieman BJ; Lerch JP; Harris S; Born HA; Peters MM; Deng P; Cameron DL; Fink KD; Beitnere U; O'Geen H; Anderson AE; Dindot SV; Nash KR; Weeber EJ; Wöhr M; Ellegood J; Segal DJ; Silverman JL
    Transl Psychiatry; 2020 Jan; 10(1):39. PubMed ID: 32066685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel UBE3A sequence variant identified in eight related individuals with neurodevelopmental delay, results in a phenotype which does not match the clinical criteria of Angelman syndrome.
    Geerts-Haages A; Bossuyt SNV; den Besten I; Bruggenwirth H; van der Burgt I; Yntema HG; Punt AM; Brooks A; Elgersma Y; Distel B; Valstar M
    Mol Genet Genomic Med; 2020 Nov; 8(11):e1481. PubMed ID: 32889787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Gene and Small Molecule Therapies for the Neurodevelopmental Disorder Angelman Syndrome.
    Copping NA; McTighe SM; Fink KD; Silverman JL
    Neurotherapeutics; 2021 Jul; 18(3):1535-1547. PubMed ID: 34528170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of a Novel Rat Model of Angelman Syndrome with a Complete Ube3a Gene Deletion.
    Dodge A; Peters MM; Greene HE; Dietrick C; Botelho R; Chung D; Willman J; Nenninger AW; Ciarlone S; Kamath SG; Houdek P; Sumová A; Anderson AE; Dindot SV; Berg EL; O'Geen H; Segal DJ; Silverman JL; Weeber EJ; Nash KR
    Autism Res; 2020 Mar; 13(3):397-409. PubMed ID: 31961493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.